Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:CLDXNASDAQ:FOLDNASDAQ:INVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsCLDXCelldex Therapeutics$20.82+3.8%$19.80$14.40▼$47.00$1.38B1.33940,207 shs724,877 shsFOLDAmicus Therapeutics$5.73-1.2%$6.40$5.72▼$12.65$1.76B0.543.03 million shs5.42 million shsINVAInnoviva$21.46+0.1%$19.33$15.70▼$22.00$1.35B0.37682,932 shs633,760 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CLDXCelldex Therapeutics0.00%+2.31%+1.61%+6.01%-39.93%FOLDAmicus Therapeutics0.00%-7.13%-13.05%-36.40%-41.35%INVAInnoviva0.00%+0.28%+14.27%+24.26%+32.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACLDXCelldex Therapeutics2.6983 of 5 stars4.43.00.00.02.60.00.0FOLDAmicus Therapeutics4.0131 of 5 stars3.42.00.04.31.80.01.9INVAInnoviva4.1481 of 5 stars3.50.00.04.22.71.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/ACLDXCelldex Therapeutics 2.89Moderate Buy$50.11140.69% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22183.11% UpsideINVAInnoviva 3.00Buy$55.00156.29% UpsideCurrent Analyst Ratings BreakdownLatest AVEO, FOLD, INVA, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.003/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28CLDXCelldex Therapeutics$7.02M196.87N/AN/A$11.26 per share1.85FOLDAmicus Therapeutics$528.29M3.34N/AN/A$0.65 per share8.82INVAInnoviva$358.71M3.76$3.43 per share6.26$11.03 per share1.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ACLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.09N/A13.33N/A-5.41%4.67%1.05%8/14/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A13.85N/A-16.15%15.77%8.41%7/29/2025 (Estimated)Latest AVEO, FOLD, INVA, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35CLDXCelldex TherapeuticsN/A21.6721.67FOLDAmicus Therapeutics2.023.342.47INVAInnoviva0.402.482.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%CLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/AINVAInnoviva99.12%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%CLDXCelldex Therapeutics4.40%FOLDAmicus Therapeutics2.20%INVAInnoviva2.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableAVEO, FOLD, INVA, and CLDX HeadlinesRecent News About These CompaniesExchange Traded Concepts LLC Grows Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)June 17 at 3:59 AM | marketbeat.comInnoviva (NASDAQ:INVA) Hits New 12-Month High - Should You Buy?June 16, 2025 | marketbeat.comPromising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA TreatmentJune 16, 2025 | tipranks.comFDA to Review Novel Oral Antibiotic for Uncomplicated GonorrheaJune 10, 2025 | empr.comInnoviva Specialty's gonorrhea antibiotic to undergo FDA reviewJune 10, 2025 | msn.comInnoviva Specialty Therapeutics Announces Acceptance Of Zoliflodacin NDA For ReviewJune 10, 2025 | kalkinemedia.comInnoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in AdultsJune 10, 2025 | businesswire.comInnoviva: A Riddle Wrapped In A Mystery Inside An EnigmaJune 8, 2025 | seekingalpha.comGAMMA Investing LLC Acquires 77,145 Shares of Innoviva, Inc. (NASDAQ:INVA)June 7, 2025 | marketbeat.comInnoviva (NASDAQ:INVA) Sets New 1-Year High - Time to Buy?June 6, 2025 | marketbeat.comTheravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth UncertaintyJune 5, 2025 | tipranks.comTheravance Biopharma Sells Trelegy Royalty Interest to GSKJune 2, 2025 | tipranks.comNuveen Asset Management LLC Has $5.32 Million Position in Innoviva, Inc. (NASDAQ:INVA)June 1, 2025 | marketbeat.comTwo Sigma Investments LP Has $4.56 Million Stock Position in Innoviva, Inc. (NASDAQ:INVA)May 29, 2025 | marketbeat.comJefferies Financial Group Inc. Has $5.14 Million Stake in Innoviva, Inc. (NASDAQ:INVA)May 28, 2025 | marketbeat.comTwo Sigma Advisers LP Lowers Stock Position in Innoviva, Inc. (NASDAQ:INVA)May 28, 2025 | marketbeat.comInnoviva, Inc. (NASDAQ:INVA) Stock Holdings Lifted by Millennium Management LLCMay 28, 2025 | marketbeat.comBank of America Corp DE Decreases Holdings in Innoviva, Inc. (NASDAQ:INVA)May 23, 2025 | marketbeat.comMan Group plc Acquires 81,891 Shares of Innoviva, Inc. (NASDAQ:INVA)May 21, 2025 | marketbeat.comTheravance Biopharma Holds 2025 Annual General MeetingMay 20, 2025 | tipranks.comZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial InfectionsMay 20, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVEO, FOLD, INVA, and CLDX Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Celldex Therapeutics NASDAQ:CLDX$20.82 +0.76 (+3.79%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$20.17 -0.65 (-3.14%) As of 06/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$5.73 -0.07 (-1.21%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.72 -0.01 (-0.09%) As of 06/18/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Innoviva NASDAQ:INVA$21.46 +0.02 (+0.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$21.46 0.00 (0.00%) As of 06/18/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
